Market Summary
USD499.49+3.70
Market Closed0.75%
TMO Alerts
TMO Stock Price
TMO RSI Chart
TMO Valuation
TMO Price/Sales (Trailing)
TMO Profitability
TMO Fundamentals
TMO Revenue
TMO Earnings
Price Action
52 Week Range
475.77609.85
(Low)(High)
Last 7 days
-1.9%
Last 30 days
-11.0%
Last 90 days
-4.5%
Trailing 12 Months
-2.2%
TMO Financial Health
TMO Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for TMO
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-30 | Pettiti Gianluca | acquired | 761,970 | 253 | 3,000 | executive vice president |
2023-08-30 | Pettiti Gianluca | sold | -1,673,310 | 557 | -3,000 | executive vice president |
2023-08-28 | Williamson Stephen | sold (taxes) | -157,633 | 545 | -289 | sr. vp and cfo |
2023-08-28 | Holmes Joseph R. | sold (taxes) | -6,721 | 545 | -12.328 | vp & chief accounting officer |
2023-08-28 | CASPER MARC N | sold (taxes) | -509,274 | 545 | -934 | chairman & ceo |
2023-08-28 | Boxer Michael A | sold (taxes) | -56,675 | 545 | -103 | svp and general counsel |
2023-08-28 | Lagarde Michel | sold (taxes) | -190,846 | 545 | -350 | executive vice president & coo |
2023-08-28 | Britt Lisa P. | sold (taxes) | -60,891 | 545 | -111 | sr. vp and chief hr officer |
2023-08-28 | Pettiti Gianluca | sold (taxes) | -148,671 | 545 | -272 | executive vice president |
2023-08-25 | Pettiti Gianluca | sold (taxes) | -204,250 | 541 | -377 | executive vice president |
Which funds bought or sold TMO recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -31.58 | -389,021 | 632,883 | -% |
2023-09-26 | DecisionPoint Financial, LLC | sold off | -100 | -11,528 | - | -% |
2023-09-26 | M Holdings Securities, Inc. | sold off | -100 | -549,000 | - | -% |
2023-09-21 | Jefferies Group LLC | added | 23.6 | 3,292,640 | 24,694,100 | 0.21% |
2023-09-21 | Baystate Wealth Management LLC | added | 214 | 108,668 | 167,742 | 0.01% |
2023-09-21 | Halpern Financial, Inc. | new | - | 6,522 | 6,522 | -% |
2023-09-20 | BARCLAYS PLC | added | 39.22 | 126,910,000 | 614,468,000 | 0.39% |
2023-09-14 | IMS Capital Management | added | 2.02 | -54,466 | 657,927 | 0.36% |
2023-09-13 | CGC Financial Services, LLC | new | - | 188,352 | 188,352 | 0.12% |
2023-09-12 | Farther Finance Advisors, LLC | added | 28.16 | 83,248 | 603,291 | 0.13% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
TMO Alerts
Schedule 13G FIlings of Thermo Fisher Scientific
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 8.30% | 32,534,676 | SC 13G/A | |
| Feb 03, 2023 | blackrock inc. | 7.9% | 30,790,122 | SC 13G/A | |
| Feb 10, 2022 | vanguard group inc | 7.89% | 31,103,788 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 7.9% | 30,982,611 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 7.82% | 30,997,381 | SC 13G/A | |
| Feb 01, 2021 | blackrock inc. | 7.4% | 29,504,221 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 7.77% | 31,187,697 | SC 13G/A | |
| Feb 06, 2020 | blackrock inc. | 7.0% | 28,202,856 | SC 13G/A |
Recent SEC filings of Thermo Fisher Scientific
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 21, 2023 | 8-K/A | Current Report | |
| Aug 31, 2023 | 4 | Insider Trading | |
| Aug 30, 2023 | 144 | Notice of Insider Sale Intent | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading | |
| Aug 29, 2023 | 4 | Insider Trading |
TMO Fair Value
Loading...
Peers (Alternatives to Thermo Fisher Scientific)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
TMO | 191.4B | 43.5B | -11.02% | -2.25% | 33.42 | 4.4 | 1.64% | -23.14% |
MTD | 23.8B | 4.0B | -11.06% | 0.30% | 26.75 | 6.01 | 2.30% | 16.37% |
ILMN | 21.6B | 4.5B | -19.01% | -28.49% | -5.15 | 4.83 | -4.92% | -21931.58% |
WAT | 16.0B | 3.0B | -3.74% | 0.37% | 23.68 | 5.34 | 3.16% | -3.93% |
BRKR | 9.1B | 2.7B | -5.72% | 17.17% | 28.6 | 3.36 | 9.64% | 16.50% |
| MID-CAP | ||||||||
NEO | 1.5B | 551.6M | -21.56% | 38.21% | -13.2 | 2.74 | 12.73% | 21.90% |
| SMALL-CAP | ||||||||
PACB | 2.0B | 146.1M | -29.45% | 38.67% | -6.32 | 13.8 | 4.72% | -55.19% |
QTRX | 1.0B | 112.0M | -0.96% | 142.38% | -15.25 | 8.96 | 0.83% | 16.42% |
ADPT | 750.7M | 189.6M | -23.79% | -27.11% | -3.93 | 3.96 | 18.74% | 17.75% |
EYPT | 267.6M | 37.3M | -25.86% | -1.39% | -2.53 | 7.17 | -9.96% | -38.49% |
HBIO | 181.9M | 114.1M | -3.40% | 66.41% | -33.5 | 1.59 | -5.49% | -48.58% |
CDXS | 138.2M | 99.2M | 10.00% | -67.33% | -2.44 | 1.39 | -26.56% | -199.52% |
CDXC | 109.3M | 80.9M | -6.41% | 18.70% | -16.83 | 1.35 | 17.20% | 77.07% |
BNGO | 97.4M | 31.5M | -23.90% | 60.11% | -0.66 | 3.09 | 35.12% | -38.47% |
Thermo Fisher Scientific News
Returns for TMO
Cumulative Returns on TMO
18.6%
10-Year Cumulative Returns
17.9%
7-Year Cumulative Returns
15.1%
5-Year Cumulative Returns
4.5%
3-Year Cumulative Returns
Risks for TMO
What is the probability of a big loss on TMO?
16.1%
Probability that Thermo Fisher Scientific stock will be more than 20% underwater in next one year
0%
Probability that Thermo Fisher Scientific stock will be more than 30% underwater in next one year.
0%
Probability that Thermo Fisher Scientific stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does TMO drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Thermo Fisher Scientific was unfortunately bought at previous high price.
Drawdowns
Financials for Thermo Fisher Scientific
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | -0.6% | 43,524 | 43,807 | 44,915 | 44,167 | 42,820 | 41,123 | 39,211 | 39,059 | 38,250 | 35,894 | 32,218 | 28,497 | 26,248 | 25,647 | 25,542 | 25,220 | 24,868 | 24,630 | 24,358 | 23,898 | 23,094 |
| Costs and Expenses | 0.4% | 36,812 | 36,672 | 36,522 | 35,097 | 33,182 | 31,323 | 29,183 | 28,498 | 27,541 | 25,957 | 24,424 | 22,542 | 21,773 | 21,067 | 20,948 | 20,710 | 20,392 | 20,713 | 20,575 | 20,306 | 19,780 |
| S&GA Expenses | -0.7% | 8,771 | 8,835 | 8,993 | 8,972 | 8,768 | 8,458 | 8,007 | 7,806 | 7,394 | 7,205 | 6,930 | 6,365 | 6,312 | 6,167 | 6,144 | 6,142 | 6,093 | 6,070 | 6,057 | 6,026 | 5,936 |
| R&D Expenses | -1.4% | 1,433 | 1,453 | 1,471 | 1,472 | 1,472 | 1,450 | 1,406 | 1,390 | 1,335 | 1,256 | 1,181 | 1,067 | 1,018 | 1,000 | 1,003 | 992 | 985 | 981 | 967 | 949 | 926 |
| EBITDA | -100.0% | - | 8,537 | 9,547 | 9,485 | 9,979 | 10,058 | 10,208 | 11,191 | 11,242 | 11,969 | 10,045 | 8,187 | 6,777 | 6,961 | 7,013 | 7,023 | 7,039 | 6,468 | 6,196 | 5,945 | 5,569 |
| EBITDA Margin | -100.0% | - | 0.19* | 0.21* | 0.21* | 0.23* | 0.24* | 0.26* | 0.29* | 0.29* | 0.33* | 0.31* | 0.29* | 0.26* | 0.27* | 0.27* | 0.28* | 0.28* | 0.26* | 0.25* | 0.25* | 0.24* |
| Interest Expenses | 20.0% | 1,068 | 890 | 726 | 618 | 573 | 547 | 536 | 521 | 537 | 552 | 553 | 549 | 569 | 613 | 676 | 712 | 740 | 756 | 667 | - | - |
| Earnings Before Taxes | -7.3% | 6,171 | 6,658 | 7,835 | 7,920 | 8,496 | 8,628 | 8,841 | 9,876 | 9,951 | 9,155 | 7,230 | 5,373 | 3,943 | 4,083 | 4,072 | 4,044 | 4,032 | 3,445 | 3,262 | 3,070 | 2,740 |
| EBT Margin | -100.0% | - | 0.15* | 0.17* | 0.18* | 0.20* | 0.21* | 0.23* | 0.25* | 0.26* | 0.25* | 0.22* | 0.19* | 0.15* | 0.16* | 0.16* | 0.16* | 0.16* | 0.14* | 0.13* | 0.13* | 0.12* |
| Net Income | -5.1% | 5,726 | 6,032 | 6,960 | 7,045 | 7,450 | 7,611 | 7,728 | 8,569 | 8,599 | 7,926 | 6,377 | 4,879 | 3,706 | 3,669 | 3,696 | 3,592 | 3,541 | 3,174 | 2,938 | 2,568 | 2,393 |
| Net Income Margin | -100.0% | - | 0.14* | 0.15* | 0.16* | 0.17* | 0.19* | 0.20* | 0.22* | 0.22* | 0.22* | 0.20* | 0.17* | 0.14* | 0.14* | 0.14* | 0.14* | 0.14* | 0.13* | 0.12* | 0.11* | 0.10* |
| Free Cashflow | -100.0% | - | 5,620 | 6,911 | 5,600 | 6,336 | 7,001 | 6,789 | 7,916 | 8,132 | 8,062 | 6,815 | 5,686 | 4,245 | 3,702 | 4,047 | 3,940 | 4,086 | 4,273 | 3,785 | 3,919 | 3,690 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | -0.6% | 94,105 | 94,658 | 97,154 | 90,536 | 90,579 | 92,747 | 95,123 | 73,600 | 67,698 | 65,931 | 69,052 | 64,061 | 61,593 | 58,688 | 58,381 | 56,729 | 57,970 | 55,596 | 56,232 | 55,078 | 55,403 |
| Current Assets | -1.1% | 19,995 | 20,209 | 25,229 | 19,299 | 18,100 | 18,776 | 20,113 | 24,724 | 19,260 | 17,685 | 21,957 | 18,234 | 15,775 | 12,738 | 11,893 | 10,514 | 11,223 | 9,939 | 10,625 | 9,566 | 9,474 |
| Cash Equivalents | -10.0% | 3,133 | 3,482 | 8,524 | 2,919 | 1,905 | 2,779 | 4,491 | 12,048 | 7,035 | 5,603 | 10,336 | 7,570 | 5,837 | 3,010 | 2,422 | 1,305 | 2,314 | 1,128 | 2,117 | 1,111 | 956 |
| Inventory | -0.2% | 5,655 | 5,664 | 5,634 | 5,722 | 5,668 | 5,483 | 5,051 | 4,906 | 4,625 | 4,342 | 4,029 | 3,829 | 3,648 | 3,454 | 3,370 | 3,308 | 3,209 | 3,124 | 3,005 | 2,982 | 2,866 |
| Net PPE | -0.7% | 9,292 | 9,354 | 9,280 | 8,628 | 8,529 | 8,448 | 8,333 | 7,049 | 6,560 | 6,133 | 5,912 | 5,180 | 4,887 | 4,736 | 4,749 | 4,420 | 4,394 | 4,192 | 4,165 | 3,978 | 3,952 |
| Goodwill | 0.3% | 43,273 | 43,140 | 41,196 | 40,488 | 41,066 | 41,721 | 41,924 | 26,909 | 26,904 | 26,823 | 26,041 | 25,782 | 25,700 | 25,614 | 25,714 | 25,624 | 25,757 | 25,236 | 25,347 | 25,142 | 25,120 |
| Current Liabilities | -11.2% | 14,112 | 15,884 | 17,010 | 11,118 | 10,997 | 12,070 | 13,436 | 7,753 | 6,925 | 6,995 | 10,304 | 6,228 | 6,013 | 5,500 | 6,197 | 5,844 | 7,509 | 5,898 | 6,147 | 5,196 | 5,980 |
| Long Term Debt | 0.2% | 29,194 | 29,135 | 28,909 | 28,150 | 29,250 | 31,389 | 32,333 | 21,688 | - | - | 19,107 | - | - | - | - | - | 16,663 | 16,812 | 17,719 | 17,760 | 17,709 |
| LT Debt, Non Current | - | - | - | - | - | - | - | - | - | 18,773 | 18,641 | 19,107 | 21,091 | 20,638 | 19,231 | 17,076 | 16,392 | - | - | 17,719 | - | - |
| Shareholder's Equity | 3.4% | 43,752 | 42,310 | 43,978 | 43,549 | 42,354 | 41,018 | 40,855 | 38,757 | 36,901 | 35,068 | 34,517 | 31,824 | 29,875 | 28,559 | 29,684 | 29,355 | 28,729 | 27,693 | 27,594 | 26,890 | 26,445 |
| Retained Earnings | 2.8% | 44,289 | 43,064 | 41,910 | 40,452 | 39,074 | 37,528 | 35,431 | 33,876 | 32,076 | 30,350 | 28,116 | 25,705 | 23,860 | 22,791 | 22,092 | 21,165 | 20,482 | 19,439 | 18,700 | 17,866 | 17,226 |
| Additional Paid-In Capital | 0.8% | 17,030 | 16,889 | 16,743 | 16,596 | 16,467 | 16,292 | 16,174 | 15,960 | 15,826 | 15,684 | 15,579 | 15,467 | 15,334 | 15,186 | 15,064 | 14,964 | 14,887 | 14,771 | 14,621 | 14,526 | 14,408 |
| Shares Outstanding | 0% | 386 | 386 | - | 392 | 392 | 392 | - | 394 | 393 | 394 | - | 396 | 395 | 397 | - | 401 | 400 | 400 | - | 402 | 403 |
| Minority Interest | -5.7% | 50.00 | 53.00 | 54.00 | 59.00 | 61.00 | 62.00 | 62.00 | - | - | - | 10.00 | - | - | - | - | - | - | - | - | - | - |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 0.2% | 7,693 | 7,681 | 9,154 | 8,124 | 8,837 | 9,536 | 9,312 | 10,194 | 10,252 | 9,911 | 8,289 | 6,863 | 5,272 | 4,680 | 4,973 | 4,861 | 4,964 | 5,114 | 4,543 | 4,608 | 4,317 |
| Share Based Compensation | -1.0% | 302 | 305 | 307 | 309 | 283 | 257 | 230 | 204 | 205 | 201 | 196 | 188 | 178 | 183 | 181 | 182 | 186 | 182 | 181 | 180 | 179 |
| Cashflow From Investing | -0.5% | -4,655 | -4,631 | -2,159 | -20,326 | -20,397 | -20,604 | -21,932 | -3,866 | -3,615 | -3,248 | -1,510 | -1,223 | -1,056 | -1,566 | -1,487 | -1,869 | -1,839 | -1,255 | -1,253 | -815 | -7,616 |
| Cashflow From Financing | 19.9% | -1,809 | -2,258 | -2,810 | 3,266 | 6,457 | 8,286 | 6,581 | -1,935 | -5,766 | -4,510 | 959 | 494 | -584 | -1,074 | -3,118 | -2,617 | -1,624 | -3,320 | -2,237 | -3,368 | 3,589 |
| Dividend Payments | 3.8% | 487 | 469 | 455 | 441 | 425 | 411 | 395 | 379 | 364 | 348 | 337 | 326 | 316 | 305 | 297 | 289 | 281 | 274 | 266 | 258 | 248 |
| Buy Backs | 0% | 4,000 | 4,000 | 3,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 2,000 | 1,500 | 2,250 | 2,250 | 2,250 | 1,500 | 1,000 | 1,250 | 1,250 | 500 | 250 | - |
TMO Income Statement
2023-07-01Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
| Revenues | ||||
| Revenues | $ 10,687 | $ 10,970 | $ 21,397 | $ 22,788 |
| Costs and operating expenses: | ||||
| Selling, general and administrative expenses | 2,145 | 2,209 | 4,264 | 4,486 |
| Research and development expenses | 345 | 365 | 691 | 729 |
| Restructuring and other costs | 183 | 24 | 295 | 26 |
| Total costs and operating expenses | 9,109 | 8,969 | 18,256 | 17,966 |
| Operating income | 1,578 | 2,001 | 3,141 | 4,822 |
| Interest income | 178 | 36 | 324 | 54 |
| Interest expense | (326) | (148) | (626) | (284) |
| Other income/(expense) | 0 | 28 | (46) | (135) |
| Income before income taxes | 1,430 | 1,917 | 2,793 | 4,457 |
| Provision for income taxes | (52) | (198) | (98) | (499) |
| Equity in earnings/(losses) of unconsolidated entities | (16) | (51) | (41) | (70) |
| Net income | 1,362 | 1,668 | 2,654 | 3,888 |
| Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest | 1 | 4 | 4 | 9 |
| Net income attributable to Thermo Fisher Scientific Inc. | $ 1,361 | $ 1,664 | $ 2,650 | $ 3,879 |
| Earnings per share attributable to Thermo Fisher Scientific Inc. | ||||
| Basic (in dollars per share) | $ 3.53 | $ 4.25 | $ 6.86 | $ 9.90 |
| Diluted (in dollars per share) | $ 3.51 | $ 4.22 | $ 6.83 | $ 9.83 |
| Weighted average shares | ||||
| Basic (in shares) | 386 | 392 | 386 | 392 |
| Diluted (in shares) | 388 | 394 | 388 | 394 |
| Product revenues | ||||
| Revenues | ||||
| Revenues | $ 6,271 | $ 7,003 | $ 12,675 | $ 15,020 |
| Costs and operating expenses: | ||||
| Cost of revenues | 3,278 | 3,516 | 6,615 | 7,071 |
| Service revenues | ||||
| Revenues | ||||
| Revenues | 4,416 | 3,967 | 8,722 | 7,768 |
| Costs and operating expenses: | ||||
| Cost of revenues | $ 3,158 | $ 2,855 | $ 6,391 | $ 5,654 |
TMO Balance Sheet
2023-07-01Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions | Jul. 01, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 3,133 | $ 8,524 |
| Accounts receivable, less allowances of $180 and $189 | 8,019 | 8,115 |
| Inventories | 5,655 | 5,634 |
| Contract assets, net | 1,467 | 1,312 |
| Other current assets | 1,721 | 1,644 |
| Total current assets | 19,995 | 25,229 |
| Property, plant and equipment, net | 9,292 | 9,280 |
| Acquisition-related intangible assets, net | 17,437 | 17,442 |
| Other assets | 4,108 | 4,007 |
| Goodwill | 43,273 | 41,196 |
| Total assets | 94,105 | 97,154 |
| Current liabilities: | ||
| Short-term obligations and current maturities of long-term obligations | 4,814 | 5,579 |
| Accounts payable | 2,423 | 3,381 |
| Accrued payroll and employee benefits | 1,310 | 2,095 |
| Contract liabilities | 2,590 | 2,601 |
| Other accrued expenses | 2,975 | 3,354 |
| Total current liabilities | 14,112 | 17,010 |
| Deferred income taxes | 2,842 | 2,849 |
| Other long-term liabilities | 4,042 | 4,238 |
| Long-term obligations | 29,194 | 28,909 |
| Redeemable noncontrolling interest | 113 | 116 |
| Thermo Fisher Scientific Inc. shareholders’ equity: | ||
| Preferred stock, $100 par value, 50,000 shares authorized; none issued | 0 | 0 |
| Common stock, $1 par value, 1,200,000,000 shares authorized; 441,398,059 and 440,668,112 shares issued | 441 | 441 |
| Capital in excess of par value | 17,030 | 16,743 |
| Retained earnings | 44,289 | 41,910 |
| Treasury stock at cost, 55,448,286 and 50,157,275 shares | (15,084) | (12,017) |
| Accumulated other comprehensive income/(loss) | (2,924) | (3,099) |
| Total Thermo Fisher Scientific Inc. shareholders’ equity | 43,752 | 43,978 |
| Noncontrolling interests | 50 | 54 |
| Total equity | 43,802 | 44,032 |
| Total liabilities, redeemable noncontrolling interest and equity | $ 94,105 | $ 97,154 |
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.